 |
10 Diseases |  |
0 Trials |
|
0 Trials |  |
112 News |  |
| «12 |
- Luminate (risuteganib) / Allegro Ophthalmics
[VIRTUAL] Impact of baseline OCT characteristics on response to risuteganib for the treatment of intermediate age-related macular degeneration (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_496;
This post hoc analysis provides preliminary insights into baseline OCT features that may help to determine likelihood of BCVA response to risuteganib. These findings will be confirmed in an upcoming larger trial.
- || Luminate (risuteganib) / Allegro Ophthalmics
Trial completion: A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate (clinicaltrials.gov) - Jul 8, 2020
P2, N=42, Completed, Sponsor: Allegro Ophthalmics, LLC
These findings will be confirmed in an upcoming larger trial. Active, not recruiting --> Completed
- || Luminate (risuteganib) / Allegro Ophthalmics
Clinical: Ally MacLeod, part of my childhood & youth, World Cups, big crowds, Killie v A*r Utd, laconic TV appearances, his pub in Killie. Helluva man, let's not forget how he & his family struggled, coped, made us aware @alzassociation @alzscot @ScotlandFA @LuminateScot @agescotland (Twitter) - Jun 3, 2020
- || Luminate (risuteganib) / Allegro Ophthalmics
👆🏻FAO: @alzscot @alzassociation @DementiaFriends @RSNOChorus @alzheimerssoc @LuminateScot @RCStweets @StAndrewsMusic @univofstandrews @Astellis (Twitter) - Jun 1, 2020
- Luminate (risuteganib) / Allegro Ophthalmics
Mechanism of Action of Risuteganib for Retinal Diseases through Protection of Retinal Pigment Epithelium (RPE) and Enhancement of Mitochondrial Functions (Exhibit Hall: Posterboard# B0184) - Mar 9, 2020 - Abstract #ARVO2020ARVO_5722;
The observations of preferential binding to RPE layers in retina and the protection of mitochondrial function in RPE cells against oxidative stress in vitro, suggest that the clinically observed therapeutic effect of risuteganib in dry AMD and DME may be associated with supporting RPE cells and maintaining mitochondrial stability and function. Such a novel MOA of risuteganib could lead to new strategies for treatment of retinal diseases.
- Luminate (risuteganib) / Allegro Ophthalmics
Risuteganib Modifies Hydroquinone-regulated Gene Expression and Protects against Hydroquinone-induced Cytotoxic Effects in Human RPE Cells (Exhibit Hall: Posterboard# A0270) - Mar 9, 2020 - Abstract #ARVO2020ARVO_3530;
HQ significantly increased F-actin aggregates (P<0.05) while RSG significantly decreased HQ-induced aggregates (P<0.05).Conclusions RSG had no adverse effects on healthy RPE cells. RSG regulated multiple pathways and protected against damaging effects mediated by HQ, implying a potential role for RSG therapy in the treatment of retinal diseases, such as AMD.
- Luminate (risuteganib) / Allegro Ophthalmics
Safety and Efficacy of Risuteganib in Intermediate Non-exudative Age-Related Macular Degeneration (Ballroom I) - Mar 9, 2020 - Abstract #ARVO2020ARVO_2459;
Furthermore, post hoc analysis provides preliminary insights into baseline anatomic features that may help to determine likelihood of BCVA response to risuteganib. These findings will be confirmed in an upcoming larger trial.
- Luminate (risuteganib) / Allegro Ophthalmics
Safety and Efficacy of Risuteganib in Intermediate Non-exudative Age-Related Macular Degeneration () - Feb 20, 2020 - Abstract #Macula2020MACULA_89;
- Luminate (risuteganib) / Allegro Ophthalmics
Primary Results from Phase 2 Study of Risuteganib (RSG) in Intermediate Dry AMD (WEST 3002 Moscone Center) - Oct 8, 2019 - Abstract #AAO2019AAO_3048;
- Luminate (risuteganib) / Allegro Ophthalmics
Safety and efficacy of risuteganib in non-exudative age-related macular degeneration – primary results from a phase 2 study (Amphitheatre Havane) - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_2060;
Risuteganib is a novel integrin inhibitor that downregulates the oxidative stress response with a potential role for the treatment of dry AMD. The safety and efficacy data from the Phase 2 study will be presented.
- Luminate (risuteganib) / Allegro Ophthalmics
Safety and efficacy of risuteganib in non-exudative age-related macular degeneration – primary results from a phase 2 study (Amphitheatre Havane) - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1811;
Risuteganib is a novel integrin inhibitor that downregulates the oxidative stress response with a potential role for the treatment of dry AMD. The safety and efficacy data from the Phase 2 study will be presented.
- Luminate (risuteganib) / Allegro Ophthalmics
Primary Results From Phase 2 Study of Risuteganib in Intermediate Dry AMD (Moscone Center EPOSTER & VIDEO TERMINALS) - Sep 5, 2019 - Abstract #AAO2019AAO_2535;
Conclusion RSG is a novel integrin inhibitor with a potential role for the treatment of intermediate dry AMD. Primary results of the Phase 2 study will be presented.
- Luminate (risuteganib) / Allegro Ophthalmics
Primary Results from Phase 2 Study of Risuteganib (RSG) in Intermediate Dry Age-Related Macular Degeneration (dAMD) (Moscone Center WEST 3002) - Sep 5, 2019 - Abstract #AAO2019AAO_1822;
- | Luminate (risuteganib) / Allegro Ophthalmics
Absolutely! Making and creating music together, live performances are the spirit of life @Arts4Dementia, @LAHFArtsHealth @IanMcCreath @ArtsHealthSW @JamesCSanderson @LuminateScot @SocialPrescrib2 @turtlesong17 (Twitter) - Jul 27, 2019
- | Luminate (risuteganib) / Allegro Ophthalmics
Trial completion date: A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate (clinicaltrials.gov) - Jul 9, 2019
P2, N=40, Active, not recruiting, Sponsor: Allegro Ophthalmics, LLC
Primary results of the Phase 2 study will be presented. Trial completion date: Jun 2019 --> Oct 2019
- || Luminate (risuteganib) / Allegro Ophthalmics
JDA Launches ML-Powered Luminate Warehouse Tasking to Intelligently Optimize Tasks in Real-Time https://t.co/kx9LXtudwy (Twitter) - May 7, 2019
- | Luminate (risuteganib) / Allegro Ophthalmics
Clinical, Journal: Eccrine ductal and acrosyringeal metaplasia in breast carcinomas: report of eight cases. (Pubmed Central) - Apr 11, 2019
These lesions invariably appeared in triple-negative carcinomas, but the cases differed in their clinical, radiological, and histological manifestations. Correct interpretation of these changes may facilitate identification of some metaplastic carcinomas.
- |||| Luminate (risuteganib) / Allegro Ophthalmics
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Phase 2 Randomized Clinical Trial of Luminate (clinicaltrials.gov) - Dec 7, 2018
P2, N=218, Completed, Sponsor: Allegro Ophthalmics, LLC
Correct interpretation of these changes may facilitate identification of some metaplastic carcinomas. Recruiting --> Completed | N=150 --> 218 | Trial completion date: Mar 2016 --> Jun 2017 | Trial primary completion date: Dec 2015 --> May 2017
- | Luminate (risuteganib) / Allegro Ophthalmics
New P2 trial: A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate (clinicaltrials.gov) - Aug 13, 2018
P2, N=40, Active, not recruiting, Sponsor: Allegro Ophthalmics, LLC
- | Luminate (risuteganib) / Allegro Ophthalmics
Enrollment change: A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion (clinicaltrials.gov) - Jul 18, 2018
P2, N=45, Completed, Sponsor: Allegro Ophthalmics, LLC
Recruiting --> Completed | N=150 --> 218 | Trial completion date: Mar 2016 --> Jun 2017 | Trial primary completion date: Dec 2015 --> May 2017 N=106 --> 45
- |||| Luminate (risuteganib) / Allegro Ophthalmics
Trial completion, Trial primary completion date: A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate (clinicaltrials.gov) - Dec 15, 2017
P2, N=105, Completed, Sponsor: Allegro Ophthalmics, LLC
N=106 --> 45 Recruiting --> Completed | Trial primary completion date: Jun 2016 --> Aug 2017
- |||| Luminate (risuteganib) / Allegro Ophthalmics
Trial completion, Enrollment change, Trial primary completion date: A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion (clinicaltrials.gov) - Jun 24, 2015
P2, N=106, Completed, Sponsor: Allegro Ophthalmics, LLC
Recruiting --> Completed | Trial primary completion date: Jun 2016 --> Aug 2017 Recruiting --> Completed | N=25 --> 106 | Trial primary completion date: Nov 2014 --> Jun 2015
- ||||| Luminate (risuteganib) / Allegro Ophthalmics
New P2 trial: A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate (clinicaltrials.gov) - May 6, 2015
P2, N=100, Recruiting, Sponsor: Allegro Ophthalmics, LLC
- ||||| Luminate (risuteganib) / Allegro Ophthalmics
New P2 trial: Phase 2 Randomized Clinical Trial of Luminate (clinicaltrials.gov) - Jan 28, 2015
P2, N=150, Recruiting, Sponsor: Allegro Ophthalmics, LLC
- | Luminate (risuteganib) / Allegro Ophthalmics
New P2 trial: A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion (clinicaltrials.gov) - Jun 1, 2014
P2, N=25, Recruiting, Sponsor: Allegro Ophthalmics, LLC
- | Luminate (risuteganib) / Allegro Ophthalmics
New P1/2 trial: A Safety And Efficacy Study Of ALG-1001 In Human Subjects With Wet Age-Related Macular Degeneration (clinicaltrials.gov) - Dec 13, 2012
P1/2, N=30, Recruiting, Sponsor: Allegro Ophthalmics, LLC
- Luminate (risuteganib) / Allegro Ophthalmics
Trial withdrawal: Safety Study of ALG- 1001 to Treat Diabetic Macular Edema (clinicaltrials.gov) - Dec 5, 2012
P1/2, N=0, Withdrawn, Sponsor: Allegro Ophthalmics, LLC
Recruiting --> Completed | N=25 --> 106 | Trial primary completion date: Nov 2014 --> Jun 2015 Recruiting --> Withdrawn
- Luminate (risuteganib) / Allegro Ophthalmics
Enrollment change: Safety Study of ALG- 1001 to Treat Diabetic Macular Edema (clinicaltrials.gov) - Dec 5, 2012
P1/2, N=0, Withdrawn, Sponsor: Allegro Ophthalmics, LLC
Recruiting --> Withdrawn N=30 --> 0
- Luminate (risuteganib) / Allegro Ophthalmics
New P1/2 trial: Safety Study of ALG- 1001 to Treat Diabetic Macular Edema (clinicaltrials.gov) - Nov 29, 2011
P1/2, N=0, Withdrawn, Sponsor: Allegro Ophthalmics, LLC